A Phase 1, Safety, Tolerability and Pharmacokinetic Profile of Intravitreous Injections of E10030 (Anti-PDGF Pegylated Aptamer) in Subjects With Neovascular Age-Related Macular Degeneration

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 31, 2007

Study Completion Date

December 31, 2008

Conditions

Age-related Macular Degeneration

Interventions

DRUG

E10030

Intravitreal injection

Trial Locations (1)

Denise Teuber, New York